Session: SUN 88-129-Acromegaly & Prolactinoma
Poster Board SUN-101
Aim: To determine the percentage of patients with acromegaly treated with SSA who received their SSA treatment less frequently than 4 weeks while maintaining safe GH levels, thus reducing financial burden for the health care system.
Methods: We reviewed the records of 67 patients (34 m and 33 f) followed-up in our centre for acromegaly and treated with SSAs: 43 were on lanreotide (Somatuline Autogel) and 24 on octreotide (Sandostatin LAR). A mean growth hormone <2.5 microgs/l and normal IGF-1 levels were used to confirm control of the disease.
Results: 8 patients (11.9%) received 3-weekly injections, 40 patients (59%) 4-weekly, 9 patients (13.4%) 6-weekly, 8 patients (11.9%) 8-weekly and 2 patients (2.9%) every 12 weeks; 16 of the patients (23.8%) had received radiotherapy and are controlled on a 3- or 4-weekly regimen. Seven patients (10.4%) on 3- or 4-weekly injections did not achieve safe growth hormone or IGF-1 levels. Amongst those on dose extension (19), all maintained safe mean GH levels. This translates to a reduction of approximately 119 injections per year leading to a substantial reduction in the cost of treatment [estimated approximately 95,000 GBP (150,000 USD) annually].
Conclusion: In our center, SSA administration can be safely reduced in at least 32% of patients with acromegaly beneficially affecting patient convenience and quality of life, as well as providing significant health cost savings. We therefore, recommend a trial of dose extension in all controlled acromegalics on SSA therapy as routine clinical practice.
Nothing to Disclose: VT, AV, NK, AG, JAHW
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters